We introduce a novel approach for the automatic classification of FDG-PET scans of subjects with Alzheimers Disease (AD) and Frontotemporal dementia (FTD). Unlike previous work in the literature which focuses on principal component analysis and predefined regions of interest, we propose the use of decision tree learning combined with empirically determined regions of interest as attributes. The...

Background Alzheimer Management By Albumin Replacement (AMBAR) is a multicenter, randomized, placebo-controlled, Phase IIb/III clinical trial that evaluated the efficacy and safety of Plasma Exchange with replacement (PE-A) in patients mild-to-moderate Alzheimer’s disease (Boada et al., Alzheimers Dement. 2020). PE-A has demonstrated an overall benefit quality life as measured by Quality Life-A...

Dementia is a clinical state characterized by loss of function in multiple cognitive domains. It is a costly disease in terms of both personal suffering and economic loss. Frontotemporal dementia (FTD) is the term now preferred over Picks disease to describe the spectrum of non-Alzheimers dementias characterized by focal atrophy of the frontal and anterior temporal regions of the brain. The pre...

Alzheimers Disease AD is an acute neuro disease that degenerates the brain cells and thus leads to memory loss progressively. It a fatal mostly affects elderly. steers decline of cognitive biological functions shrinks successively, which in turn known as Atrophy. For accurate diagnosis disease, cutting edge methods like machine learning are essential. Recently, has gained lot attention populari...

Abstrak: Lansia berisiko mengalami penurunan fungsi kognitif atau alzheimers yaitu ketika kesulitan mengingat, mempelajari hal-hal baru, berkonsentrasi, membuat keputusan yang memengaruhi kehidupan sehari-hari. Salah satu upaya mencegah terjadinya adalah dengan mengonsumsi pangan sumber vitamin B12, omega-3 dan aktivitas senam otak. Tujuan kegiatan ini meningkatkan pengetahuan pralansia lansia ...

Fluorodeoxyglucose (FDG) positron emission tomography (PET) measures the decline in the regional cerebral metabolic rate for glucose, offering a reliable metabolic biomarker even on presymptomatic Alzheimer's disease (AD) patients. PET scans provide functional information that is unique and unavailable using other types of imaging. However, the computational efficacy of FDG-PET data alone, for ...